header logo image


Page 37«..1020..36373839..5060..»

Archive for the ‘Biotechnology’ Category

Look Vir Biotechnology (VIR) Stock Where Its Heading? – News Welcome

Saturday, February 8th, 2020

Vir Biotechnology (VIR) Stock Volatility Indicators To Watch:

Volatility of the Vir Biotechnology remained at 23.33% over last week and shows 11.80% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 2.71.

Vir Biotechnology (VIR) has a market capitalization of $2.21B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock declined -14.36% to value at $22.81 on Monday trading session. VIR recorded volume of 1199133 shares in most recent trading session as compared to an average volume of 268.65K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. The stock EPS is $-1.26 against its recent stock value of $22.81 per share.

Looking into the Profitability indicators on Vir Biotechnology stock we analyze the stocks Profitability ratios.

Profitability Spotlight for Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -7.95% during the period of last 5 trading days. The stock maintained for the month at 87.70%. The stock noted year to date 2019 performance at 81.35% and changed about 61.74% over the last three months. The stock is now standing at -21.36% from 52 week-high and is situated at 95.74% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 63.39.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently up 34.32% from its 20 days moving average and trading 58.72% up the 50 days moving average. The stock price has been seen performing along above drift from its 200 days moving average with 59.36%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Read the original here:
Look Vir Biotechnology (VIR) Stock Where Its Heading? - News Welcome

Read More...

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs – Benzinga

Saturday, February 8th, 2020

The following is a roundup of top developments in the biotech space over the last 24 hours:

(Biotech stocks that hit 52-week highsFeb. 5.)

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More here:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Benzinga

Read More...

Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? – Simply Wall St

Thursday, January 30th, 2020

Today well evaluate GeneReach Biotechnology Corp. (GTSM:4171) to determine whether it could have potential as an investment idea. To be precise, well consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First of all, well work out how to calculate ROCE. Second, well look at its ROCE compared to similar companies. Then well determine how its current liabilities are affecting its ROCE.

ROCE measures the return (pre-tax profit) a company generates from capital employed in its business. In general, businesses with a higher ROCE are usually better quality. Overall, it is a valuable metric that has its flaws. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that one dollar invested in the company generates value of more than one dollar.

Analysts use this formula to calculate return on capital employed:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) (Total Assets Current Liabilities)

Or for GeneReach Biotechnology:

0.11 = NT$72m (NT$713m NT$61m) (Based on the trailing twelve months to September 2019.)

Therefore, GeneReach Biotechnology has an ROCE of 11%.

View our latest analysis for GeneReach Biotechnology

One way to assess ROCE is to compare similar companies. Using our data, GeneReach Biotechnologys ROCE appears to be around the 9.5% average of the Medical Equipment industry. Regardless of where GeneReach Biotechnology sits next to its industry, its ROCE in absolute terms appears satisfactory, and this company could be worth a closer look.

GeneReach Biotechnology has an ROCE of 11%, but it didnt have an ROCE 3 years ago, since it was unprofitable. That implies the business has been improving. The image below shows how GeneReach Biotechnologys ROCE compares to its industry, and you can click it to see more detail on its past growth.

When considering this metric, keep in mind that it is backwards looking, and not necessarily predictive. ROCE can be misleading for companies in cyclical industries, with returns looking impressive during the boom times, but very weak during the busts. ROCE is only a point-in-time measure. Since the future is so important for investors, you should check out our free report on analyst forecasts for GeneReach Biotechnology.

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To counteract this, we check if a company has high current liabilities, relative to its total assets.

GeneReach Biotechnology has total assets of NT$713m and current liabilities of NT$61m. As a result, its current liabilities are equal to approximately 8.6% of its total assets. With low current liabilities, GeneReach Biotechnologys decent ROCE looks that much more respectable.

This is good to see, and while better prospects may exist, GeneReach Biotechnology seems worth researching further. GeneReach Biotechnology shapes up well under this analysis, but it is far from the only business delivering excellent numbers . You might also want to check this free collection of companies delivering excellent earnings growth.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See more here:
Is GeneReach Biotechnology Corp. (GTSM:4171) Investing Effectively In Its Business? - Simply Wall St

Read More...

Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry – InvestorsObserver

Thursday, January 30th, 2020

Oncolytics Biotech, Inc. (ONCY) is near the top in its industry group according to InvestorsObserver. ONCY gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Oncolytics Biotech, Inc. gets a 94 rank in the Biotechnology industry. Biotechnology is number 55 out of 148 industries.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Oncolytics Biotech, Inc. (ONCY) stock is trading at $3.11 as of 9:57 AM on Monday, Jan 27, a loss of -$0.16, or -5.05% from the previous closing price of $3.27. The stock has traded between $3.00 and $3.35 so far today. Volume today is below average. So far 349,770 shares have traded compared to average volume of 2,557,054 shares.

To see InvestorsObserver's Sentiment Score for Oncolytics Biotech, Inc. click here.

See the article here:
Is Oncolytics Biotech, Inc. (ONCY) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Read More...

A case of wholehearted biotechnology adoption – The Hindu

Thursday, January 30th, 2020

In the Editorial page article, The flawed spin to Indias cotton story (January 23, 2020), there are unfounded claims about a technology that has in reality been a boon to farmers across the world.

The first point made in the article is that GM cotton covers 95% of the area under cotton and that there are no choices for farmers. The fact: Indian farmers have voted for choice of seeds with biotechnologies by planting hybrid cotton biotech seeds on over 90% of the countrys cotton acreage. They want seeds and technologies that provide optimal yield, income and convenience in cultivation. Today, they choose from over 800 hybrid Bt cotton seed brands from over 40 Indian and global seed companies, with five approved in-the-seed insect protection Bt cotton technologies and non-Bt varietal cotton seeds. Farmers have not shown any preference for planting non-Bt cotton seeds including the quantity supplied along with the Bt cotton seed by seed companies as per regulatory guidelines.

Several key studies by third-party economists and sociologists have established that 85% of hybrid Bt cotton seed farmers and farm labourers invested in better education for children; 77% reported better intake of nutritious food; 75% reported better health of their family members; 64% invested on the health of livestock; female workers on Bt cotton fields earned an average 55% higher income; and 42.4 crore additional days of rural employment have been generated, thereby doubling cotton production.

Indias farmers are the ones who have reposed trust in biotechnology, making India the worlds second largest cotton producer and exporter by doubling cotton production over the past decade.

Cotton Corporation of India data show that the highest production of 398 lakh bales of cotton in India was achieved in 2013-14, valued at around 72,000 crore. Additional incomes were generated from cotton seeds oil (1.3 million tons) and cotton seed oilmeal (11 million tons) worth 13,000 crore and 22,000 crore, respectively. The Bt cotton seed market is about 3,000 crore, making it hardly 2.5% of the total value generated.

The articles second point is about low productivity as compared to the global scene. The fact is that technology has not only increased yields but also greatly reduced pesticide use. Biotechnology in cotton, post its introduction in 2002, has led to transformational changes in Indias cotton cultivation. These have helped increase cotton yields by over 1.8 times from 241 kg/hectare in 2002-2003 to 541 kg/hectare in 2018-2019. A BKS-CSD study shows that the significant increase in farmer incomes from higher yields and reduced pesticide use has generated additional farm income of over 42,300 crore. India is moving to first place as the largest producer of cotton in the world.

However, it is not just the technology that increases yields. Indias farmers face numerous uncertainties and crop management challenges, affecting farm yield and incomes; knowledge of cultivation and correct agronomic practices can make a significant impact. This is being addressed by numerous extension efforts.

There is an opportunity to increase yields further in India when compared to other countries that have been using even more advanced GM traits than what is being used in India. New technology introduction has stopped in India since 2005, affecting growth of yields.

The articles third point is about the availability of low cost manual labour. The fact is that one of the major challenges lies in securing labour to conduct field operations. Today, labour accounts for over 58% of a farmers cost of cultivation per acre. In a fast-evolving global market, Indias farmers instead need the best technologies to remain competitive.

The next claim is about varieties offering farmers increased benefits than hybrid cotton seeds. The fact is that Indian farmers who were using varieties for years switched to hybrids in the mid-1980s mainly because of the enormous benefits. Cotton Advisory Board data show that Indias cotton yields which were at 169 kg/hectare in 1980-81 increased to 278 kg/hectare in 2000-01 and then 542 kg/ hectare in 2016-17.

The writers argument that High Density Planting (HDP) took place in various countries after introduction of biotech cotton is inaccurate. Planting rates are determined by several agronomic and environmental conditions and not based on biotech versus non-biotech. There is also no change in the seed rate in any of the countries in which biotech cotton has been adopted. HDP has done well in India because of the better quality of germplasm.

Also, Turkey is not a large cotton producer. USDA statistics in 2017-18 shows that India leads with 35m bales, followed by China (28m bales), the U.S. (21m bales), Brazil (9m bales) and Australia (5m bales). All of them are GM cotton countries, contributing to more than 90% of global cotton production. GM cotton was introduced in Brazil in 2006-07.

India also produces hybrid cotton seed because of the availability of labour to carry out the hand pollination at reasonable cost; this is not available in the U.S., Brazil, Australia and China. Hybrid cotton has delivered not only higher yields but also provided resistance to some pests and diseases.

The article also claims that Indian farmers need to buy seeds repeatedly. The fact is that not just biotech cotton, but all hybrid seeds lose their benefits if replanted, creating reduced and erratic yields. New seeds help farmers sustain high yields year on year.

In the case of biotech cotton in India, it is the farmers who adopted the technology wholeheartedly because they saw a solution in it to some of their biggest on-field pest challenges. The choice made by the Indian farmer to plant hybrid cotton seeds on over 90% of cotton acreage, and see increased cotton production is testament to the value created by better seeds, technologies and farming practices when compared with the alternative of low tech seed and insecticide sprays.

Bt cotton was released in varieties by some public institutions but it did not get much traction. There is always a debate about the use of hybrids versus varieties in any crop. The writer appears to be giving too much power to the seed industry in terms of influencing the farmer to prefer hybrids over varieties. This has not happened in the case of rice, mustard, many oilseeds, and pulses in which the farmers grow varietal crops in 90-100% of the area. The lesson is that the farmer adopts technologies which are beneficial to him and does not go by the recommendations of the industry or any other persons.

Seeds with biotechnologies have helped conserve biodiversity: with higher production from the same area, the expansion of agricultural land into forest areas has been slowed.

A one-sided depiction not only harms agriculture and the industry but also spreads misconceptions about biotechnology.

Ram Kaundinya is Director General, Federation of Seed Industry of India (FSII), New Delhi

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Go here to read the rest:
A case of wholehearted biotechnology adoption - The Hindu

Read More...

Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 47.94% : What to Expect? – The InvestChronicle

Thursday, January 30th, 2020

Vir Biotechnology, Inc. (VIR) is priced at $22.47 after the most recent trading session. At the very opening of the session, the stock price was $20.63 and reached a high price of $26.29, prior to closing the session it reached the value of $21.31. The stock touched a low price of $20.21.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -18.22% during the 52-week period from high price, and 92.87% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $27.48.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 2.14 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 78.69%, having the revenues showcasing 48.32% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.19B, as it employees total of 217 workers.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 68.37%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 67.66%. In the last 20 days, the companys Stochastic %K was 70.12% and its Stochastic %D was recorded 78.51%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 78.69%. The shares increased approximately by 1.27% in the 7-day charts and went down by 35.85% in the period of the last 30 days. Common stock shares were driven by 48.32% during last recorded quarter.

Read more here:
Vir Biotechnology, Inc. (VIR) distance from 20-day Simple moving Average is 47.94% : What to Expect? - The InvestChronicle

Read More...

GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells – Benzinga

Thursday, January 30th, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions.

ATLANTA (PRWEB) January 29, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions. Trauma situations often do not allow for adequate blood typing due to time restrictions, so the GIOSTAR/HEAMGEN red blood cells address that need effectively.

"There are three main problems for blood transfusions," stated Dr. Anand Srivastava, Founder and Chairman of GIOSTAR. "First we have to match the blood type. Second, there's not enough blood available every single time. And third, when we transfer blood from one person to another person, there is always a chance of the transfer of disease."

Watch a feature interview with Dr. Anand Srivastava on The DM Zone with host Dianemarie Collins.

The World Health Organization (WHO) published the first detailed analysis on the global supply and demand for blood in October 2019 and found that 119 out of 195 countries do NOT have enough blood in their blood banks to meet hospital needs. In those nations, which include every country in central, eastern, and western sub-Saharan Africa, Oceania (not including Australasia), and south Asia are missing roughly 102,359,632 units of blood, according to World Health Organization (WHO) goals. While total blood supply around the world was estimated to be around 272 million units, in 2017, demand reached 303 million units. That means the world was lacking 30 million units of blood, and in the 119 countries with insufficient supply, that shortfall reached 100 million units.

The global market opportunity for GIOSTAR/HEAMGEN technology presents not only a profitable and scalable business opportunity but also a significant social and environmental impact. The global market is estimated to be at least $ 85 Billion/year.

GIOSTAR/HEAMGEN has identified early entry global markets to include Military, Trauma, Asia (replace Hepatitis C contaminated blood products), Africa (AIDS contaminated blood), Newborns, Thalassemia patients, Allosensitized sickle cell disease patients. South Sudan was found to have the lowest supply of blood, at 46 units per 100,000 people. In fact, the country's need for blood was deemed 75 times greater than its supply. In India, which had the largest absolute shortage, there was a shortfall of nearly 41 million units, with demand outstripping supply by over 400 percent. Strategic investments are needed in many low-income and middle-income countries to expand national transfusion services and blood management systems. Oncology is a major user of blood transfusion but if countries don't have the capacity to manage the bulk of oncology, it will limit complex surgery options.

GIOSTAR/HEAMGEN has acquired the exclusive license to the patent for the technique for stem cell proliferation from University of California San Diego (UCSD). The founding team of GIOSTAR/HEAMGEN is comprised of the scientists and clinicians who were involved in creating the Intellectual Property at UCSD and has already achieved PROOF OF CONCEPT - the optimized lab scale proliferation of mature red blood cells - at UCSD as part of their research.

GIOSTAR/HEAMGEN is currently looking for strategic partnerships (Contact Doug@DMProductionsLLC.com) to accelerate the development of donor-independent red blood cells manufacturing capabilities and advance the proof of concept work already done (patented) around the manufacture of safe, universal donor, human red blood cells. GIOSTAR/HEAMGEN will also develop a full automated proprietary bioreactor using robotic technology to produce abundant quantities of red blood cells with a goal for cost-effective commercialization of fresh, human, universal donor Red Blood Cells (RBCs).

ABOUT GIOSTAR

Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company's primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is world's leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a pioneer and a world-renowned authority in the field of Stem Cell Biology, Cancer and Gene therapy. Several governments and organizations including USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership, a group of esteemed scientists and clinicians have developed and established Stem Cell Therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe.

For the original version on PRWeb visit: https://www.prweb.com/releases/giostar_announces_medical_breakthrough_in_biotechnology_and_lifesciences_to_manufacture_abundant_safe_red_blood_cells_from_stem_cells/prweb16854975.htm

Read more here:
GIOSTAR Announces Medical Breakthrough in Biotechnology and Lifesciences To Manufacture Abundant, Safe Red Blood Cells From Stem Cells - Benzinga

Read More...

Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup – The Indian Express

Thursday, January 30th, 2020

Written by Anuradha Mascarenhas | Pune | Published: January 29, 2020 5:20:12 am Dr M K Bhan

Hailing him as the strong pillar on which the Department of Biotechnology (DBT) stood today, secretary Dr Renu Swarup said noted paediatrician and former DBT secretary Dr M K Bhan, who died on January 26, changed the landscape of the biotechnology sector and was among those scientists who had been able to fulfil the dream of introducing a rotavirus vaccine, now part of the universal immunisation programme. Swarup worked closely with Dr Bhan for over a decade.

Dr Bhan pioneered the first indigenously developed rotavirus vaccine and the highest tribute to him would be to take forward his legacy, Dr Swarup said, adding that he was a visionary and his death had left a void that will never get filled.

The rotavirus vaccine was developed from scratch and the government introduced it in the public health programme from 2016.

Generous and passionate about building up young people, Dr Bhan was fiercely committed to our country and its science, but gentle in his approach to individuals and rigorous in his approach to institutions. Dr Bhan was unique and special, Prof Gagandeep Kang, executive director of Translational Health Science and Technology Institute, Faridabad, told The Indian Express.

Prof Chittaranjan Yajnik, noted diabetologist and director of the diabetes unit at KEM hospital in Pune said his death was a massive loss to Indian science. His legacy will guide us in solving problems, said Prof Yajnik, who was his close friend.

Prof Yajnik added that he was a visionary scientist who handled science, its translation and management seamlessly. Dr Bhan was instrumental in promoting new biotechnology institutes in different parts of the country and involving scientists of multiple specialties to interact with each other under the umbrella of biotechnology.

We are now observing the fruits of this approach. He was instrumental in setting up the vaccine field trial unit at KEM hospital, which has contributed significantly to rotavirus research and related studies, Prof Yajnik said.

Dr Bhan was my mentor; as a young trainee gastroenterologist visiting AIIMS, he inspired us to inculcate a systematic approach to clinical problems and as a teacher of epidemiology he shared his belief that public health research was the need of the hour, said Dr Ashish Bawdekar, consultant paediatric gastroenterologist at KEM hospital.

Dr Bawdekar further talked of his close involvement with Dr Bhan, who was the DBT secretary during the development of the Indian rotavirus vaccine.

He was extremely nationalistic and felt Indian scientists were as good as others in the world and would not accept any interference from foreign funders. It was unbelievable what he could foresee and then, more importantly, do something about it, he said.

Dr Sanjay Juvekar, head of the Vadu Rural Health Programme said their team will cherish the experience shared with Dr Bhan on the rotavirus vaccine research,

He was in favour of translational research that could yield results with immediate benefits to the public. Apart from his immense contribution towards the indigenous rotavirus vaccine, he was also instrumental in the identification of zinc deficiency as the cause behind several abnormalities observed in children, said Dr Manoj Kumar Bhat, director of National Centre for Cell Science (NCCS).

Senior scientist at NCCS, Dr Yogesh Shouche, said during his tenure, Dr Bhan came up with several new initiatives not only in health but also in other sectors like agriculture and food processing.

For all the latest Pune News, download Indian Express App

Read the rest here:
Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup - The Indian Express

Read More...

B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates – Yahoo…

Saturday, January 18th, 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) just released its yearly report and things are looking bullish. Results overall were solid, with revenues arriving 9.7% better than analyst forecasts at 40m. Higher revenues also resulted in substantially lower statutory losses which, at 0.58 per share, were 9.7% smaller than analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what analysts' statutory forecasts suggest is in store for next year.

Check out our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

XTRA:BNN Past and Future Earnings, January 18th 2020

Following the latest results, B.R.A.I.N. Biotechnology Research and Information Network's four analysts are now forecasting revenues of 43.5m in 2020. This would be a solid 8.6% improvement in sales compared to the last 12 months. Per-share statutory losses are expected to see a sharp uptick, reaching 0.47. Before this earnings announcement, analysts had been forecasting revenues of 40.0m and losses of 0.29 per share in 2020. While next year's revenue estimates increased, there was also a large cut to EPS expectations, suggesting the consensus has a bit of a mixed view of these results.

There was no major change to the consensus price target of 17.80, with growing revenues seemingly enough to offset the concern of growing losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on B.R.A.I.N. Biotechnology Research and Information Network, with the most bullish analyst valuing it at 24.00 and the most bearish at 9.50 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Zooming out to look at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up both against past performance, and against industry growth estimates. We would highlight that B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, with forecast 8.6% increase next year well below the historical 15%p.a. growth over the last five years. By way of comparison, other companies in this market with analyst coverage, are forecast to grow their revenue at 3.8% next year. So it's pretty clear that, while B.R.A.I.N. Biotechnology Research and Information Network's revenue growth is expected to slow, it's still expected to grow faster than the market itself.

Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider market. The consensus price target held steady at 17.80, with the latest estimates not enough to have an impact on analysts' estimated valuations.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for B.R.A.I.N. Biotechnology Research and Information Network going out to 2024, and you can see them free on our platform here.

Story continues

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read the original post:
B.R.A.I.N. Biotechnology Research and Information Network AG Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo...

Read More...

Unified Biotechnology Regulation Website Launched – The National Law Review

Saturday, January 18th, 2020

Thursday, January 16, 2020

In a coordinated effort, the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), and the Environmental Protection Agency (EPA) launched a Unified Website for Biotechnology Regulation on January 9, 2020. The website serves to streamline information regarding agriculture biotechnology products, which are regulated by FDA, USDA, and EPA. The implementation of the website is in response to the June 2019 Executive Order issued by President Donald Trump on Modernizing the Regulatory Framework for Agricultural Biotechnology Products. The Unified Website for Biotechnology Regulation complements prior joint actions such as the Coordinated Framework for the Regulation of Biotechnology, an Obama administration effort to reform the biotechnology regulatory process by enhancing transparency, predictability, and efficacy. Mintz has previously covered these coordinated efforts here.

Agriculture biotechnology products are products created through genetic engineering of plants, animals, and microbes. Each agency has a role in regulating biotechnology products: USDA has authority to approve all releases of genetically modified organisms (GMOs) to ensure they do not create an environmental hazard; EPA must approve all crops that contain insect-killing genes; and FDA is responsible for evaluating whether GMOs are safe to eat. However, because of the interrelatedness of this area, agency regulatory oversight can be disjointed and unclear. Additionally, the advancement of technology can cause confusion in interpreting the regulatory requirements of each agency. Therefore, a primary goal of the website is to enhance customer service by allowing users to submit questions directly to the three agencies, as well as through providing a Frequently Asked Questions page.

The Unified Website for Biotechnology Regulation does not alter the regulatory process concerning agriculture biotechnology products. Instead, the website acts as an interactive archive containing information about the federal review process, while also enabling users to submit questions to the regulatory agencies with the expectation of a coordinated response. According to the FDA Press Release, "[t]he goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

The website launch follows the October 2018 FDA announcement for its Plant and Animal Biotechnology Action Plan, which provides a risk-based regulatory approach to the oversight of plant and animal-derived products of biotechnology, with a focus on safety and effectiveness. One of the action plan's priorities is to coordinate a new biotechnology approach with EPA and USDA to clarify oversight of genome-edited products. According to FDA Commissioner Stephen Hahn, M.D.: This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace . . . Our approach balances our internationally respected, science-based review standards with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

While the Unified Website for Biotechnology Regulation is a step towards meeting the goals set in the June 2019 Executive Order, additional efforts are needed to better coordinate biotechnology product regulation as technology continues to advance.

1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

Link:
Unified Biotechnology Regulation Website Launched - The National Law Review

Read More...

Biotechnology and Healthcare is the best performing IT fund sector – What Investment

Saturday, January 18th, 2020

Low cost of capital has fueled exceptional returns for biotech and health stocks but will near zero cost financing last?

Biotechnology & Healthcare was the top performing investment company sector of the last decade producing a return of 491% from 2010 to 2019, compared to a return of 198% for the average investment company over the same period, according to the Association of Investment Trusts (AIC).

The UK Smaller Companies and Global Smaller Companies sectors were the second and third best performing sectors of the decade and delivered 379% and 330% respectively. European Smaller Companies (10th) also featured in the top ten.

Meanwhile the best performing investment companies over the past decade came from a variety of sectors, but companies in the UK Smaller Companies sector featured most strongly, making four appearances within the top ten.

Volta Finance was the best performing member company over the decade. The company from the Debt Structured Finance sector produced an impressive 959% share price total return from 1 January 2010 to 31 December 2019. It was followed by Lindsell Train in the Global sector, up 730%, and Baillie Gifford Shin Nippon from the Japanese Smaller Companies sector, up 678% over the same period.

Annabel Brodie-Smith, communications director of the AIC said: Its encouraging to see a diverse spectrum of investment company sectors perform so strongly over the last decade. While Biotechnology & Healthcare was the top performing sector by some margin, two UK equity sectors made it into the top ten despite the Brexit referendum and subsequent lack of clarity surrounding the UKs exit.

The closed-ended investment company structure lends itself particularly well to illiquid alternative investments and over the past decade the Private Equity and Infrastructure sectors have both delivered particularly strong returns. Three smaller company sectors feature in the top ten best performers, demonstrating that investment companies are the best vehicle for holding smaller companies which can be hard to sell in times of stress. In addition, investors who have favoured investment companies to gain overseas exposure via the Japan, Global and North America sectors have been handsomely rewarded.

Its always interesting to look back at the best performing companies, but its important to remember that past performance is not an indicator of future returns. Investment companies cover a broad variety of sectors, risk profiles and geographical exposure to match a range of investor needs. When investing you should consider your objectives and the level of risk you are willing to take and, if you have any concerns, you should speak to a financial adviser.

Jason Hollands, managing director, business development and communications at Tilney Investment Management Services said: The last decade has seen huge advances in medical discovery. When combined with an extraordinarily supportive, post global crisis environment for risk assets i.e. low cost of capital thats fueled exceptional returns for biotech and health stocks.

While there is no reason to doubt further advancements in medical science, we wont remain locked in a world of near zero real financing costs forever. Of particular relevance is mounting pressure across the global for greater controls over drug pricing, given the spiraling costs to health services. This could be particularly relevant if the Democrats win the US Presidential election as their nominees have been vocal on this as well as calling for a much more interventionist role for the state in the massive US healthcare market.

With regards to the overall observations below. The broad theme is that smaller companies across a variety of markets have been amongst the best performing parts of the market. Ironically this has taken place over a period during which investors have increasingly shunned them in the clamour for passive products that are overwhelming skewed to large-cap companies. Frankly, the more smaller companies are ignored, the greater the potential available for active managers to add value in this space by spotting winners that the wider market has yet to discover.

Further reading: Investment Trusts: A beginners guide

Read more:
Biotechnology and Healthcare is the best performing IT fund sector - What Investment

Read More...

Should You Be Pleased About The CEO Pay At Avecho Biotechnology Limited’s (ASX:AVE) – Yahoo Finance

Saturday, January 18th, 2020

Ross Murdoch has been the CEO of Avecho Biotechnology Limited (ASX:AVE) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for Avecho Biotechnology

Our data indicates that Avecho Biotechnology Limited is worth AU$7.9m, and total annual CEO compensation was reported as AU$404k for the year to December 2018. We think total compensation is more important but we note that the CEO salary is lower, at AU$351k. We examined a group of similar sized companies, with market capitalizations of below AU$289m. The median CEO total compensation in that group is AU$379k.

So Ross Murdoch receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.

You can see a visual representation of the CEO compensation at Avecho Biotechnology, below.

ASX:AVE CEO Compensation, January 14th 2020

On average over the last three years, Avecho Biotechnology Limited has grown earnings per share (EPS) by 65% each year (using a line of best fit). It achieved revenue growth of 310% over the last year.

This shows that the company has improved itself over the last few years. Good news for shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

With a three year total loss of 80%, Avecho Biotechnology Limited would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

Ross Murdoch is paid around what is normal the leaders of comparable size companies.

We think that the EPS growth is very pleasing, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Avecho Biotechnology (free visualization of insider trades).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Originally posted here:
Should You Be Pleased About The CEO Pay At Avecho Biotechnology Limited's (ASX:AVE) - Yahoo Finance

Read More...

Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth – Simply Wall St

Saturday, January 18th, 2020

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought wed take a look at whether Vir Biotechnology (NASDAQ:VIR) shareholders should be worried about its cash burn. In this report, we will consider the companys annual negative free cash flow, henceforth referring to it as the cash burn. Well start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

See our latest analysis for Vir Biotechnology

A companys cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, Vir Biotechnology had cash of US$320m and no debt. Importantly, its cash burn was US$130m over the trailing twelve months. That means it had a cash runway of about 2.5 years as of September 2019. Thats decent, giving the company a couple years to develop its business. You can see how its cash balance has changed over time in the image below.

Some investors might find it troubling that Vir Biotechnology is actually increasing its cash burn, which is up 39% in the last year. And we must say we find it concerning that operating revenue dropped 4.0% over the same period. Taken together, we think these growth metrics are a little worrying. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Even though it seems like Vir Biotechnology is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash to fund growth. By comparing a companys annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$1.6b, Vir Biotechnologys US$130m in cash burn equates to about 8.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another years growth by issuing some new shares to investors, or even by taking out a loan.

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Vir Biotechnologys cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, were not too worried about its rate of cash burn. While we always like to monitor cash burn for early stage companies, qualitative factors such as the CEO pay can also shed light on the situation. Click here to see free what the Vir Biotechnology CEO is paid..

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more:
Companies Like Vir Biotechnology (NASDAQ:VIR) Are In A Position To Invest In Growth - Simply Wall St

Read More...

Sofinnova Partners Announces the Promotion of Michael Krel to Partner of Industrial Biotechnology Team – Yahoo Finance

Saturday, January 18th, 2020

Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the promotion of Michael Krel, PhD, to Partner of the Industrial Biotechnology team. Mr. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.

"This promotion recognizes Michaels excellent skills in the field of industrial biotech, and also reinforces the leading role that Sofinnova Partners is playing in this emerging sector," said Denis Lucquin, Managing Partner of Sofinnova Partners. "We look forward to working with Michael in his new role, and to the continued value his experience and deep subject area expertise bring to our pioneering work in this space."

Mr. Krel said, "It has been a privilege to serve the firm, and to help pioneer its development in Industrial Biotech. I look forward to continuing our work in this important area, and to the potential impact these investments will have globally."

Sofinnova Partners Industrial Biotech franchise is dedicated to start-ups with a specific emphasis on synthetic biology, food, feed, agriculture, materials and chemicals, and represents more than 200 M under management.

Mr. Krel joined Sofinnova Partners as a Senior Associate in 2013 and has been involved in the venture capital firms investment activities in industrial biotech since then. Mr. Krel is an observer on the board of Comet Bio and a board member of EnobraQ and Afyren.

Prior to joining Sofinnova Partners, Michael spent six years in industrial biotech start-ups, holding business development positions. Additionally, Michael was a consultant focused on R&D strategic and organizational issues.

Mr. Krel has a graduate degree in engineering from Ecole Polytechnique and holds a PhD in organic chemistry from Paris X Orsay University.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005847/en/

Contacts

Press: Media: Kate BarretteRooneyPartners LLC+1 212 223 0561kbarrette@rooneyco.com

France Anne ReinS&I+33 6 03 35 92 05anne.rein@strategiesimage.com

Read this article:
Sofinnova Partners Announces the Promotion of Michael Krel to Partner of Industrial Biotechnology Team - Yahoo Finance

Read More...

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics – Yahoo Finance

Saturday, January 18th, 2020

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market. FDA 510(k) cleared with an indication for the management of wounds, Excellagen Aesthetics is intended for use following facial rejuvenation procedures, including post-laser surgery, post-chemical peels, and post- skin ablation. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen Aesthetics has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.

Olaregen is rolling out Excellagen Aesthetics with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered. Americans spent an estimated $8 billion on surgical and non-surgical aesthetic dermatology procedures in 2018 when there were over 340,000 facial rejuvenation performed.

Scott Emmens, Senior Vice President of Sales and Business Development at Olaregen commented, We have been working closely with the aesthetic dermatology community, and Excellagen Aesthetics is being tested with some leading dermatologists who are conducting case studies to evaluate the efficacy of our cellular tissue product in wound management as measured by patient reported down-time as well as patient satisfaction with post-treatment care. We are enthusiastic about the early response from patients and doctors who have tried the product after facial rejuvenation procedures including micro-needling and laser skin resurfacing, two procedures that result in post-treatment pain and significant healing times that limit daily activities. We look forward to engaging with the dermatology community to introduce Excellagen Aesthetics and show how our FDA-cleared product can be used to the benefit of their patients and their practice.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

About Olaregen Therapeutix

Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. in bone and joint regeneration comprise the current pipeline. The company's mission is to become a significant force in regenerative medicine and advance the science of healing.

Story continues

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Original post:
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics - Yahoo Finance

Read More...

Is Menlo Therapeutics Inc (MNLO) Stock a Good Buy in Biotechnology – InvestorsObserver

Saturday, January 18th, 2020

Menlo Therapeutics Inc (MNLO) is near the top in its industry group according to InvestorsObserver. MNLO gets an overall rating of 58. That means it scores higher than 58 percent of stocks. Menlo Therapeutics Inc gets a 72 rank in the Biotechnology industry. Biotechnology is number 60 out of 148 industries.

Click Here to get the full Stock Score Report on Menlo Therapeutics Inc (MNLO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Menlo Therapeutics Inc (MNLO) stock is trading at $6.10 as of 12:18 PM on Tuesday, Jan 14, a rise of $0.50, or 8.93% from the previous closing price of $5.60. The stock has traded between $5.50 and $6.44 so far today. Volume today is light. So far 132,809 shares have traded compared to average volume of 181,677 shares.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Excerpt from:
Is Menlo Therapeutics Inc (MNLO) Stock a Good Buy in Biotechnology - InvestorsObserver

Read More...

Astellas and Adaptimmune team up in CAR-T development – European Biotechnology

Saturday, January 18th, 2020

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.

Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.

Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.

Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.

In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.

Read the original:
Astellas and Adaptimmune team up in CAR-T development - European Biotechnology

Read More...

Chromatography in Biotechnology Market Growth 2020-2026 with Competitive Landscape and Top Regions – Weekly Wall

Saturday, January 18th, 2020

Global Chromatography in Biotechnology market 2020 in depth research by industry competitive landscape, size, growth rate, strategy, trends and forecast 2026.

The global Chromatography in Biotechnology market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Chromatography in Biotechnology market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Chromatography in Biotechnology market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Get the Sample of this Report@https://www.qyresearch.com/sample-form/form/1456217/global-chromatography-in-biotechnology-market

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Chromatography in Biotechnology market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Market Segments Covered:

The following players are covered in this report:Bio-Rad Laboratories Inc.Danaher Corp.MilliporeSigmaQiagenScion InstrumentsThermo Fisher Scientific Inc.PerkinelmerGe Healthcare Life SciencesAntec ScientificAsynt Ltd.Chromatography in Biotechnology Breakdown Data by TypeGas ChromatographyThin Layer ChromatographySupercritical Fluid ChromatographyLiquid ChromatographyHPLC/UHPLCAffinity ChromatographyChromatography in Biotechnology Breakdown Data by ApplicationCancer Research CentersCancer HospitalPharmaceuticalPathological SectorsCompanies and Academic InstitutionsOthers

Regions Covered in the Global Chromatography in Biotechnology Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Chromatography in Biotechnology market Exhaustive research on innovation and other trends of the global Chromatography in Biotechnology market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report segments the global Chromatography in Biotechnology market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Chromatography in Biotechnology market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1456217/global-chromatography-in-biotechnology-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Chromatography in Biotechnology market

Chapter 2: Evaluating the leading manufacturers of the global Chromatography in Biotechnology market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Chromatography in Biotechnology market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Chromatography in Biotechnology Market Growth 2020-2026 with Competitive Landscape and Top Regions - Weekly Wall

Read More...

Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio – Business Wire

Sunday, January 12th, 2020

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global biotechnology reagents market since 2014 and the market is poised to grow by USD 37.98 billion during the period 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request free sample pages

Read the 136-page report with TOC on Biotechnology Reagents Market Analysis Report by Technology (Chromatography, In-vitro diagnostics, Polymerase chain reaction, Cell culture, and Others), Geography (Americas, APAC, and EMEA), and the Segment Forecasts, 2019-2023.

https://www.technavio.com/report/global-biotechnology-reagents-market-industry-analysis

The market is driven by the high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, increasing stem cell and biomedical research is anticipated to boost the growth of the biotechnology reagents market.

The market is observing a significant rise in the demand for biotechnology reagents in diagnostic and therapeutic applications. This is due to advances in technologies such as cell structure, recombinant DNA and biotherapeutics, and emerging neurosciences and proteomics disciplines. The demand for ready-to-use reagents is also growing significantly in clinical laboratories and hospitals as they ensure minimal calculation, dilution, and pipetting errors. They also help reduce the duration of the diagnostic procedure and prevent sample contamination. These factors are crucial in driving the growth of the global biotechnology reagents market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Biotechnology Reagents Market Companies:

Agilent Technologies

Agilent Technologies operates the business through segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Erythrocyte-Lysing Reagent without Fixative, EasyLyse, Erythrocyte-Lysing Reagent, Uti-Lyse, and miRNA qPCR Detection Reagents.

BD

BD operates the business through segments such as BD Medical, BD Life Sciences, and BD Interventional. The company offers a wide range of biotechnology reagents. BD OptiBuild, CD20 PE Clone L27 (ASR), and CD2 APC Clone L303.1 (also known as L303) (ASR) are some of its key offerings.

Bio-Rad Laboratories

Bio-Rad Laboratories operates the business through segments such as life science, clinical diagnostics, and others. iScript RT-qPCR Sample Preparation Reagent, Kovacs Reagent, Anti-D Reference Reagent are some of its key offerings.

GENERAL ELECTRIC

GENERAL ELECTRIC operates the business across various segments such as power, renewable energy, oil & gas, aviation, healthcare, transportation, lighting, and capital. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Amersham ECL Detection Reagents, CDP-Star Detection Reagents, and PDEA Thiol Coupling Reagent.

Merck KGaA

Merck KGaA operates the business across segments such as healthcare, life science, and performance materials. The company offers a wide range of biotechnology reagents. Solvents for Liquid Chromatography LiChrosolv, Reagents for Acylation, and Silylation Derivatization Reagent are some of the key offerings of the company.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Technavio has segmented the biotechnology reagents market based on the technology and region.

Biotechnology Reagents Technology Outlook (Revenue, USD Billion, 2019 - 2023)

Biotechnology Reagents Regional Outlook (Revenue, USD Billion, 2019 - 2023)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare include:

Global Affinity Chromatography Reagents Market Global affinity chromatography reagents market by end-users (pharmaceutical and biotechnology industry, food and beverage industry, cosmetic industry, and others) and geography (Asia, Europe, North America, and ROW).

Global Molecular Biology Enzymes, Kits, and Reagents Market Global molecular biology enzymes, kits, and reagents market by end-users (biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic institutes and research organizations) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Read more from the original source:
Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio - Business Wire

Read More...

BIRAC Supported Biotechnology Park And Incubation Centre In Rajasthan Soon – IndianWeb2.com

Sunday, January 12th, 2020

A biotechnology park and incubation centre will be set up in Rajasthan for which a Memorandum of Understanding (MoU) will be signed between the Centre and the state government, Union Secretary, Department of Biotechnology, Renu Swaroop said on Friday.

The park and incubation centre will provide an opportunity to conduct research in the field of biotechnology and employment to the youth, she said.

Swaroop was addressing the State Biotech Cohort Meeting, which was attended by vice chancellors, directors and deans of all universities having biotechnology courses, representatives from institutes conducting research in biotechnology and start-ups associated with it.

Swaroop said the Centre will provide full support and assistance to promote biotechnology in Rajasthan.

The biotechnology park and incubation centre will be set up with the support of Biotechnology Industry Research Assistance Council (BIRAC).

She said utility of biotechnology is increasing in every field, including health, agriculture and agriculture production, industry, edible food, among others. There is a need to promote biotechnology, and encouraging it will give pace to industrial development and research, she added.

Rajasthan Department of Science and Technology Secretary Mugdha Sinha said bio-informatics, biomedical engineering and nano medicine will be encouraged in the state.

The Rajasthan government recently launched Nirogi Rajasthan (Healthy Rajasthan) campaign and all possible assistance through bio-informatics will be provided to strengthen it, she added.

Biotechnology ecosystem and start-ups will be improved in the state with the help from Centre, she said. PTI AG

Like this content? Sign up for our daily newsletter to get latest updates.

See the article here:
BIRAC Supported Biotechnology Park And Incubation Centre In Rajasthan Soon - IndianWeb2.com

Read More...

Page 37«..1020..36373839..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick